Publisher： Adis International
ISSN： 1173-8324
Source： Inpharma, Vol.1, Iss.1655, 2008-01, pp. : 19-19
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
The prasugrel new drug application (NDA) is still under discussion with the US FDA
Inpharma, Vol. 1, Iss. 1661, 2008-01 ,pp. :
Access to resources
Recommend
US FDA to review bladder cancer risks for pioglitazone
Reactions Weekly, Vol. 1, Iss. 1320, 2010-01 ,pp. :
Imatinib for priority review by US FDA for GIST recurrence.
Inpharma, Vol. 1, Iss. 1654, 2008-01 ,pp. :
The US Government Accountability Office is to review a drug approval process used by the FDA
Inpharma, Vol. 1, Iss. 1633, 2008-01 ,pp. :